12 de novembro de 2024 08:07:02 ART
Research on the efficacy of Iverheal 12 Mg, which contains ivermectin (an antiparasitic medication), is primarily focused on its use for treating parasitic infections such as strongyloidiasis, onchocerciasis, and scabies. Ivermectin has also been studied for its potential use in treating other conditions, including viral infections like COVID-19, although such uses remain controversial.
Key Research Areas on Iverheal (Ivermectin):
-
Treatment of Parasitic Infections:
- Ivermectin, including the Iverheal 12 Mg formulation, has been well-researched and is widely used for treating various parasitic infections. This includes conditions like river blindness (onchocerciasis), lymphatic filariasis, and intestinal strongyloidiasis.
- Studies have been conducted by public health organizations, including the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), which have highlighted ivermectin as an effective treatment for these diseases.
-
COVID-19 Studies:
- Ivermectin gained attention during the COVID-19 pandemic due to its in vitro antiviral activity against the SARS-CoV-2 virus. A number of clinical trials were initiated to investigate whether ivermectin could be effective in preventing or treating COVID-19. However, results have been mixed and many health authorities, including the FDA, WHO, and the European Medicines Agency (EMA), have emphasized that more robust clinical evidence is needed.
- Some well-known studies in this area include research conducted by the University of Melbourne, Monash University, and the National Institutes of Health (NIH), though these studies have faced criticisms regarding sample sizes, methodologies, or conclusions.
-
Studies on Efficacy and Safety:
- Clinical studies on the efficacy and safety of ivermectin in various parasitic infections have been published in peer-reviewed journals such as The Lancet, Journal of the American Medical Association (JAMA), and Iverheal 12 Mg New England Journal of Medicine.
- Research has established ivermectin's safety profile when used for approved parasitic infections, with side effects typically being mild and temporary (e.g., dizziness, nausea).
Prominent Institutions and Researchers:
- World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) have conducted extensive research and provide guidelines on the use of ivermectin for parasitic diseases.
- University of Melbourne, Monash University, and National Institutes of Health (NIH) have been involved in some of the research surrounding ivermectin’s use for COVID-19.
- Researchers from various universities and pharmaceutical companies have contributed to studies on ivermectin’s applications for other parasitic diseases.
The efficacy of Iverheal 12 Mg has been studied extensively in the context of parasitic infections, with prominent research from global health organizations. Its use in other conditions, such as COVID-19, remains under investigation, with mixed findings. As always, it is essential to follow medical guidance and take ivermectin for approved indications.
